CIPLA vs THEMISMED: Stock Comparison

Cipla Ltd vs Themis Medicare Limited

Live data: 22 July 2026, 2:36 PM IST • Source: NSE and company filings

Cipla Ltd is the larger company by market capitalisation. Cipla Ltd shows a lower P/E, a higher ROE and a higher dividend yield, while Themis Medicare Limited shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Cipla Ltd and Themis Medicare Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, CIPLA is more favourable on 8 of 13 scored metrics and THEMISMED on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CIPLA is the larger company
₹1.14 L Cr vs ₹1,004 Cr
P/E Ratio
CIPLA has a lower P/E
29.83x vs 938.33x
P/B Ratio
THEMISMED has a lower P/B
2.6x vs 3.36x
EPS
CIPLA has higher earnings per share
₹48.01 vs ₹0.12
Dividend Yield
CIPLA has a higher dividend yield
0.9% vs 0.43%
Revenue Growth (TTM YoY)
THEMISMED has faster revenue growth
6.7% vs -2.1%
EPS Growth (TTM YoY)
THEMISMED has faster EPS growth
0% vs -54.6%
Qtr Sales Growth
THEMISMED has stronger quarterly sales growth
6.74% vs -2.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCIPLATHEMISMED
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricCIPLATHEMISMED
Live Price₹1,411.6₹108.35
Day Change-1.46%-3.56%
Volume12.9 L68,186
52-Week High₹1,673₹148
52-Week Low₹1,165.7₹64.95
Distance from 52W High-15.62%-26.79%

Valuation

MetricCIPLATHEMISMED
Market Cap₹1.14 L Cr₹1,004 Cr
P/E Ratio29.83x938.33x
P/B Ratio3.36x2.6x
EPS₹48.01₹0.12
Book Value₹426.25₹43.06
Dividend Yield0.9%0.43%

Growth

MetricCIPLATHEMISMED
Revenue Growth (TTM YoY)-2.1%6.7%
EPS Growth (TTM YoY)-54.6%0%
Qtr Sales Growth-2.8%6.74%
Qtr Profit Growth-54.6%192%

Profitability & Leverage

MetricCIPLATHEMISMED
ROE11.6%0.29%
ROCE15.5%2.74%
Net Margin13.96%0.33%
Operating Margin20.9%-2.9%
Debt to Equity0.02x25.11x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricCIPLATHEMISMED
Promoter Holding9.17%57.5%
FII Holding22.56% 1.37 pp0.11% 0.06 pp
DII Holding31.97% 1.25 pp0.01%
Public Holding16.25% 0.12 pp32.78% 0.05 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Cipla Ltd and Themis Medicare Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.